Get Social With Us

Mabs Continue to Drive Growth of Biopharmaceutical Market

With the approval of Humulin, the modern biotechnology era began in 1982 and now celebrating its 35th year, the biopharma industry has grown tremendously, launching nearly 225 recombinant biopharmaceuticals. As indicated in Figure 1, the 221 currently marketed products have generated an unprecedented $169B in global sales in 2016. [image_with_text image='http://www.bptc.com/wp-content/uploads/2017/06/Figure-1-002.jpg'...

Read More

Trump’s Budget Slams Biotech

Let’s be honest. This was never going to be a love affair with a fairy tale ending. Even before he took office, President Donald Trump wasn’t a friend to the U.S. biopharmaceutical industry. Last December, in his Person of the Year interview with Time magazine, he said, “I’m going to...

Read More

Emerging Therapies: CMO’s Tackle Biomanufacturing Challenges

Innovative cell and gene therapies and the resurgent interest in ADC’s (antibody drug conjugates) are emerging therapies that are creating these challenges. The roundtable discussion entitled; Outsourcing and Biomanufacturing Challenges for Emerging Therapies, at BIO 2016 focused on demands for CMO services associated with these therapies. Patti Seymour, Senior Consultant...

Read More